High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy

By Eastham James A  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 291-295

Informa Healthcare

Access to resources Recommend Favorite

Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer

By Eastham James A  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 1, 2004-01 ,pp. : 39-46

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

By Kumar Aalok   Kennecke Hagen F.   Renouf Daniel J.   Lim Howard J.   Gill Sharlene   Woods Ryan   Speers Caroline   Cheung Winson Y.  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 527-534

Blackwell Publishing

Access to resources Recommend Favorite

A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy

By Sfoungaristos Stavros   Perimenis Petros  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1421-1436

Informa Healthcare

Access to resources Recommend Favorite

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

By von Minckwitz Gunter   Conrad Bettina   Reimer Toralf   Decker Thomas   Eidtmann Holger   Eiermann Wolfgang   Hackmann John   Möbus Volker   Marmé Frederik   Potenberg Jochem   Stickeler Elmar   Simon Eike   Thomssen Christoph   Huober Jens   Denkert Carsten   Alfer Joachim   Jackisch Christian   Nekljudova Valentina   Burchardi Nicole   Loibl Sibylle   von Minckwitz Gunter  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3639-3648

Blackwell Publishing

Access to resources Recommend Favorite